The present invention relates to a system and methods for evaluating and tracking the operation of the menstrual cycle and treating undesirable trends associated with the menstrual cycle. Various aspects of the system and methods described herein rely upon the operation of diagnostic tests specially configured to evaluate a bodily fluid for the presence or absence of hormones or analytes, and more specifically configured to evaluate a bodily fluid for at least the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 μg/mL-10 μg/mL. The results from one or more diagnostic tests are interpreted in accordance with the teachings of the system. The interpretations are useful in accordance with facilitating treatments associated with medical conditions correlated to the generated interpretations, optionally delivered during a consultation with a medical provider during a telemedicine consultation, the treatments optionally comprising dietary changes incorporating the consumption of certain seeds to mitigate hormonal imbalances.

A method for determining male infertility includes detecting abnormal expression of sex-determining gene on X chromosome (SDX) or SDX protein using a test kit.

The present invention relates to automated methods for isolating fetal cells from a sample, such as a blood sample, derived from a pregnant woman. The isolated fetal cells can be used for identifying genetic abnormalities in the fetal DNA.

Disclosed are methods and systems using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the detection and/or analysis of progesterone metabolites, such as progesterone sulfates, in biological samples. In some cases, the amount of progesterone sulfate may be used to distinguish whether gestational pruritus of the skin is an early symptom of (ICP) or due to benign pruritus gravidarum.

The present invention provides a method of diagnosing endometriosis and/or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and/or protein in the sample; c) detecting a level of expression of a BCL6 gene and/or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and/or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and/or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and/or protein greater than the level of expression of the SIRT1 gene and/or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and/or protein that is greater than the level of expression of the BCL6 gene and/or protein of the control subject or population of control subjects.

Methods and compositions for detecting or determining a subjects risk of developing placenta accreta spectrum (PAS) are provided. Biomarkers are described that can be useful in detecting PAS in the second or third trimester of pregnancy.

The present disclosure provides peptides that specifically bind to maternal autoantibodies that are generated in the mother or potential mother against the endogenous polypeptide antigen neuron specific enolase (NSE) protein. The peptides described herein are useful for determining a risk of an offspring for developing an autism spectrum disorder (ASD) by detecting the presence of maternal autoantibodies in a biological sample of the mother or potential mother. The peptides or mimotopes thereof can also be administered to the mother or potential mother to block the binding between maternal autoantibodies and their antigens, thereby neutralizing the maternal autoantibodies.

Compositions and methods for predicting due date and time to birth for a pregnancy with significantly higher accuracy than current clinical methods. The compositions and methods for predicting due date and time to birth for a pregnancy can also identify those pregnancies that will deliver earlier than the due date derived from Last Menstrual Period (LMP) and/or obstetric ultrasonography (US) dating.

Provided herein are devices and methods for monitoring biofluids related to ovulation. Such devices include the use of electrochemical aptamer-based (EAB) sensors.

Embodiments of a method and/or system for facilitating characterization of one or more conditions can include: generating a set of target-associated molecules; generating a reference-associated set of molecule; facilitating generation of at least one spike-in mixture; determining one or more abundance metrics based on an analysis of the at least one spike-in mixture; and facilitating the characterization of the one or more conditions based on the one or more abundance metrics.